Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia
NCT00612105 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia
- Lead sponsor
- Bausch Health Americas, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- December 31, 2009
- Enrollment
- 187 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.
postherpetic neuralgia